Pharmaceuticals & Biopharmaceuticals

Suzhou – October 02, 2026 -- Novartis has agreed to pay Abogen Biosciences an upfront fee of USD 575 million to secure worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, with total deal value reaching up to approximately USD 7.2 billion if all milestones and options are exercised.

Novartis secures exclusive worldwide license to Abogen's lead autoimmune asset ABO2203

The licensing and option agreement grants Novartis an exclusive global license to ABO2203, which Abogen describes as the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. The molecule uses mRNA to direct endogenous production of T-cell engagers in vivo, targeting B-cell depletion through a mechanism the companies say differs from traditional recombinant T-cell engagers.

Milan – October 02, 2026 -- Hansoh Pharma's dual-biased GLP-1/GIP receptor agonist Olatorepatide (HS-20094) achieved a mean weight loss of 19.3% at Week 48 in the 15 mg dose group of a Phase III Chinese trial, with no plateau observed in the weight-loss curve.

The data, presented as a Late-breaking Abstract oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting running September 28 to October 2, 2026 in Milan, come from the LIGHTEN study, a multicenter, randomized, double-blind, placebo-controlled trial enrolling 604 Chinese adults with overweight or obesity.

Trial enrolled 604 participants across four dose arms over 48 weeks

Participants with a BMI of 28 kg/m2 or above, or 24-28 kg/m2 with a weight-related comorbidity, were randomized 1:1:1:1 to once-weekly subcutaneous Olatorepatide at 5mg, 10mg or 15mg, or placebo. A total of 90.1% completed the full 48-week treatment period.

Granite Bay, Calif. – October 02, 2026 -- GMP Labeling Inc. is marking Manufacturing Day 2026 by positioning its nearly 40-year domestic production history as a hedge against global supply chain disruption for pharmaceutical and biotechnology manufacturers. The California-based company, founded in 1987, manufactures quality control labels, sample identification tags, and equipment status markers used across regulated production lines.

Label failures can halt regulated production lines

Material inconsistencies or shipping delays in compliance labeling can interrupt manufacturing workflows, complicate federal audits, and compromise quality records, according to the company. Robin Kalsbeek, General Manager of GMP Labeling, said a label functions as a critical element of traceability and compliance rather than a minor supply item in biotechnology and medical manufacturing settings.

London – October 02, 2026 -- Curaleaf International's Que Medical Inhalation Device (QMID) has become the first cannabis inhalation device to secure registration from Australia's Therapeutic Goods Administration, clearing the way for clinicians to prescribe a standardized-dosing device in a market that has treated more than one million patients since 2016.

TGA Grants Class IIb Status to QMID on October 02, 2026

The device, developed with Jupiter Research LLC, was listed in the Australian Register of Therapeutic Goods as a Class IIb Medical Device, marking the first regulatory approval in Australia for a device delivering Cannabis Sativa L. extracts via patient inhalation. The approval follows a multi-year regulatory process and arrives one year after QMID received EU Medical Device Registration.

Cary, N.C. – October 02, 2026 -- SAS and North Carolina State University have launched the SAS Think & Do Tank, a two-year pilot research partnership applying data and AI to human health, nutrition and environmental resilience challenges, 50 years after SAS originated from an NC State agricultural research project.

Partnership targets faster drug discovery through translational predictive biology

One of the initiative's first research efforts focuses on translational predictive biology, combining studies in living systems with advanced lab models such as organoids and organ-on-chip technologies that mimic human organ function. NC State researchers aim to build predictive models that help identify promising treatments earlier, explain why interventions succeed or fail, and cut the time and cost of moving new therapies toward clinical use.

Salt Lake City – October 02, 2026 -- Banner Capital has formed Seaway Group and signed a definitive agreement to acquire three medical device manufacturing businesses -- Seaway Plastics Engineering, MME Group and Wright Engineered Plastics -- in a transaction expected to close in the fourth quarter of 2026, subject to customary closing conditions.

Seaway Group becomes the third platform in Banner Capital Fund II

The deal follows Banner Capital's prior platform launches of Western Pavement Services and Roof Restoration Group, extending the Salt Lake City-based private equity firm's push into essential, founder-led businesses beyond its traditional commercial-services focus.

San Diego – October 02, 2026 -- Avimer Bio and structural biologists at Spain's National Cancer Research Centre (CNIO) have published computational methods for building self-assembling protein cages with atomic precision, detailed in the Journal of the American Chemical Society (JACS). The study tackles a long-standing design challenge: predicting protein architecture when building blocks bend during assembly.

Sarasota, Fla. – October 01, 2026 -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) will send CEO Kelvin Cooper, Ph.D., to three separate industry conferences this month, placing the clinical-stage antimicrobial developer in front of both investors and infectious-disease specialists within an eight-day window.

CEO to address investor audiences at two New York events in mid-October

Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City, followed by a presentation at the ThinkEquity Conference on October 15, 2026, also in New York City. Both appearances target biotechnology investors evaluating the company's pipeline.

Boston – October 01, 2026 -- HoneyNaps, an AI-based sleep health technology company, has completed registration as a clinical research organization (CRO) with South Korea's National Enterprise for Clinical Trials (KoNECT), broadening its role in pharmaceutical and medical device trials worldwide.

HoneyNaps secures CRO registration with KoNECT, expanding multicenter trial capacity

The company has supported clinical trials involving more than 10,000 participants and can now operate multicenter, multidisciplinary studies under its new CRO status. The registration formalizes HoneyNaps' position as a provider of standardized sleep data analysis for pharmaceutical companies, medical device developers, and research organizations.

Tel Aviv, Israel – October 01, 2026 -- Lutris Pharma reported that its topical B-Raf inhibitor LUT014 achieved Treatment Success in 71.8% of patients with EGFR inhibitor-induced acneiform rash, compared with 38.5% on placebo (p=0.003), in updated Phase 2 data presented at the 35th EADV Congress in Vienna.

LUT014 0.1% gel cuts clinician-assessed rash severity and patient symptom burden

Among the composite endpoint's components, 56.4% of patients on LUT014 0.1% achieved at least a one-grade improvement on the CTCAE v5.0 acneiform rash scale versus 15.4% on placebo (p=0.0002). Using the FACT-EGFRI-18 patient-reported symptom score, 53.8% of treated patients reported at least a five-point improvement versus 28.2% on placebo (p=0.021).